Maria Kotowska

Maria Kotowska

Auto-generated profile, based on publicly available information

Maria Kotowska

Department of Pediatric Gastroenterology and Nutrition, The Medical University of Warsaw, Warsaw, Poland

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2001 in The Journal of Pediatrics
Verified
Journal Article
Closed access
HSHania Szajewska
Hania Szajewska
MKMaria Kotowska
Maria Kotowska
JMJacek Z. Mrukowicz
Jacek Z. Mrukowicz
MAMalgorzata Arma′Nska
Malgorzata Arma′Nska
WMWieslaw Mikolajczyk
Wieslaw Mikolajczyk


1 May 2011 in Inflammatory Bowel Diseases
Verified
Journal Article
Closed access
ARAndrzej Radzikowski
Andrzej Radzikowski
ABAleksandra Banaszkiewicz
Aleksandra Banaszkiewicz
IŁIzabella Łazowska-Przeorek
Izabella Łazowska-Przeorek
UGUrszula Grzybowska-Chlebowczyk
Urszula Grzybowska-Chlebowczyk
HWHalina Woś
Halina Woś
PAPiotr Albrecht
Piotr Albrecht

19 November 2017
Verified
Book Chapter
Closed access
PDF file
KKKatarzyna Karolewska-Bochenek
Katarzyna Karolewska-Bochenek
PGPawel Grzesiowski
Pawel Grzesiowski
ABAleksandra Banaszkiewicz
Aleksandra Banaszkiewicz
AGAgnieszka Gawronska
Agnieszka Gawronska
MKMaria Kotowska
Maria Kotowska
ILIzabella Lazowska-Przeorek
Izabella Lazowska-Przeorek

1 July 2015 in Inflammatory Bowel Diseases
Verified
Journal Article
Closed access
ABAleksandra Banaszkiewicz
Aleksandra Banaszkiewicz
BTBrygida Targońska
Brygida Targońska
KKKinga Kowalska-Duplaga
Kinga Kowalska-Duplaga
KKKatarzyna Karolewska-Bochenek
Katarzyna Karolewska-Bochenek
ASAgnieszka Sieczkowska
Agnieszka Sieczkowska
PAPiotr Albrecht
Piotr Albrecht
There are only a few studies on immune response to pneumococcal vaccines in patients with inflammatory bowel disease (IBD); all of them assessed polysaccharide vaccines only. The aim of the study was to evaluate the immunogenicity and safety of 13-valent pneumococcal conjugate vaccine (PCV13) in IBD pediatric patients compared with healthy controls. This was a multicenter, prospective, and controlled study on children and adolescents aged 5 to 18 years with IBD with no history of pneumococcal immunization. The subjects for the study belonged to one of the following groups: patients with IBD on no immunosuppressive therapy (group A), those on tumor necrosis factor agents or immunomodulators (group B), and healthy controls (group C). The study population received 1 intramuscular injection of PCV13. The primary outcome measure was adequate vaccine response defined as postvaccination titer ≥0.35 μg/mL to all 13 serotypes. Geometric mean titers and geometric mean titer rises were measured for all serotypes. The evidence of local and systemic adverse effects for 5 days after the vaccine was registered. A total of 178 subjects (122 patients and 56 controls) completed the study course. There was no significant difference in the rate of adequate vaccine response between patients with IBD and controls measured 4 to 8 weeks after vaccination (90.4% versus 96.5%, P = 0.5281). Children in group A had higher geometric mean titer rises than children in group B (P = 0.0369). There were no serious adverse events related to PCV13 during the study. PCV13 is both immunogenic and safe in pediatric patients with IBD.